Machine Learning–Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND & AIMS: Immunochemotherapy (IO-chemo) has become standard care for patients with unresectable intrahepatic cholangiocarcinoma (iCCA), but benefit of adding IO varies greatly among individuals. We sought to develop a system to identify patients most likely to benefit from this treatment based on individualized treatment effect (ITE) estimation. METHODS: This study included patients with unresectable iCCA who underwent either IO-chemo or chemotherapy alone (chemo). Patients were enrolled from three discovery and seven external validation centers. Target trial emulation was employed to obtain unbiased average treatment effect estimation, and a causal machine-learning model was used to estimate heterogeneous treatment effects for IO-chemo. Based on predicted ITE, patients were stratified into high-benefit, no- to moderate-benefit, and negative-benefit groups, with overall survival used as the primary end point. RESULTS: The discovery cohort included 1485 patients; the external validation cohort included 562 patients. In the high-benefit group, compared with chemo, the hazard ratio (HR) for IO-chemo was 0.39 (95% CI, 0.30-0.52; p < 0.001), with mortality reduced by 24.1%, 31.2%, and 28.5% at 12, 24, and 36 months, respectively. In the no- to moderate-benefit group, IO-chemo did not differ from chemo (HR, 0.91; 95% CI, 0.70-1.18; p = 0.488). In the group with negative predicted ITEs, IO-chemo was associated with shorter OS than chemo (HR, 1.91; 95% CI, 1.47-2.48; p < 0.001). In the external validation cohort, the corresponding HRs were 0.45 (95% CI, 0.30-0.68; p < 0.001), 0.62 (95% CI, 0.42-0.93; p = 0.018), and 1.93 (95% CI, 1.28-2.91; p = 0.002), respectively. CONCLUSIONS: A causal machine learning-based model can estimate individualized treatment effects of immunochemotherapy in patients with unresectable intrahepatic cholangiocarcinoma, enabling clinically meaningful benefit stratification. IMPACT AND IMPLICATIONS: The overarching goal of intrahepatic cholangiocarcinoma (iCCA) management is to deploy biomarkers that identify patients most likely to benefit from immunochemotherapy and thus enable personalized therapy, but little research has examined how clinicians choose between chemotherapy and immunochemotherapy beyond head-to-head efficacy comparisons or efforts to define subgroups suited to a single regimen. Built on a causal machine-learning (ML) framework, the Causal ML-Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma model described here offers a validated, clinically practical tool to quantify the benefit of immunochemotherapy in iCCA. In this study, 17 clinical variables were used to reliably identify patients most likely to benefit from immunochemotherapy and to predict long-term survival. By focusing on individualized treatment effects rather than average treatment effects, the model provides a strong foundation for future trials that seek to operationalize intelligent treatment selection and pushes precision immunochemotherapy for iCCA closer to routine practice. CLINICAL TRIAL NUMBER: NCT06849193.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Machine Learning–Guided Personalized Immunochemotherapy Strategies in Intrahepatic Cholangiocarcinoma
- Date Crossref
- 01/08/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Zhongda Hospital Southeast University pays non établi dans la noticeÉtablissement de santé
-
Chinese Academy of Medical Sciences & Peking Union Medical College pays non établi dans la noticeUniversité ou école supérieure
-
First Affiliated Hospital of Zhengzhou University Department of Interventional Radiology pays non établi dans la noticeÉtablissement de santé
-
Kunming Medical University Department of Radiology pays non établi dans la noticeUniversité ou école supérieure
-
Chinese PLA General Hospital pays non établi dans la noticeÉtablissement de santé
-
The 309th Hospital of Chinese People's Liberation Army pays non établi dans la noticeÉtablissement de santé
-
Jiangsu Cancer Hospital Department of Medical Oncology pays non établi dans la noticeÉtablissement de santé
-
Nanjing Medical University pays non établi dans la noticeUniversité ou école supérieure
-
University of Science and Technology of China Department of Radiology pays non établi dans la noticeUniversité ou école supérieure
-
Soochow University Department of Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Jiangsu University Department of Radiology pays non établi dans la noticeUniversité ou école supérieure
-
Jintan People's Hospital pays non établi dans la noticeÉtablissement de santé
Zhongda Hospital Southeast University, Chinese Academy of Medical Sciences & Peking Union Medical College et Department of Interventional Radiology — First Affiliated Hospital of Zhengzhou University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.